Diseases of the Kidney & Urinary Tract, Phase II
Exploring Metformin's Impact on Kidney Health in FSGS Patients
Volunteers
Health Professionals
Trial Purpose and Description
We're exploring how well and safely Metformin (MF) can work alongside other treatments for FSGS, a kidney disease. We're also looking into how FSGS reacts at a cellular level to Metformin, which could help design future trials and understand how targeting specific cellular processes might treat FSGS.
Eligibility Criteria
Inclusion criteria:
- Participants must be 18 years of age or older, but =or <80 years of age at the time of the informed consent
- Kidney Biopsy confirming FSGS
- Therapeutic plan by treating physician for treatment using glucocorticoids.
- eGFR of >30 ml/min/m 2
Exclusion criteria:
- Liver disease
- Diabetes mellitus diagnosis at the time of biopsy or need for oral hypoglycemic agents/insulin
- Kidney biopsy with non-FSGS glomerulonephritis or secondary FSGS.
- Diagnosis of Dementia
- Allergy or sensitivity to Metformin
- Platelet count <100,000/ml; INR >1.5; bleeding diathesis or blood thinner use contraindicating biopsy.
- Current pregnancy or desire to become pregnant during the study period
- Currently enrolled in (or completed within the past 30 days) a study of an investigational drug or device
- Trial withDepartment of the Army
- Start Date07/31/2023
- End Date12/31/2027
Principal Investigator
Sub-Investigators
- Last Updated03/19/2024
- Study HIC#2000035723